

Consolidated Financial Results

for the Nine Months Ended September 30, 2022

[IFRS]

November 10, 2022

Company name: PeptiDream Inc. Tokyo Stock Exchange
 Stock code: 4587 URL <https://www.peptidream.com/>
 Representative: Patrick C. Reid, President & Chief Executive Officer
 Inquiries: Yuko Okimoto, Head of Investor Relations
 Scheduled filing date of quarterly securities report: November 11, 2022
 Scheduled starting date of dividend payments: —
 Supplementary briefing materials on quarterly financial results: No
 Explanatory meeting on quarterly financial results: No

TEL: +81-44-223-6612

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2022 (January 1, 2022 to September 30, 2022)

(1) Consolidated operating results

	Revenue		Core operating profit		Operating profit		Profit before tax	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine Months ended September 30, 2022	11,208	43.3	143	(96.4)	(426)	—	(368)	—
Nine Months ended September 30, 2021	7,819	—	4,034	-	4,034	—	3,841	—

	Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%
Nine Months ended September 30, 2022	(186)	-	(896)	—
Nine Months ended September 30, 2021	2,475	-	3,415	—

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Nine Months ended September 30, 2022	(1.44)	(1.44)
Nine Months ended September 30, 2021	19.25	19.06

(2) Consolidated financial position

	Total assets	Net assets	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of September 30, 2022	51,257	24,472	24,472	47.7
As of December 31, 2021	27,034	25,350	25,350	93.8

2. Payment of Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year ended December 31, 2021	-	0.00	-	0.00	0.00
Fiscal Year ending December 31, 2022	-	0.00	-		
Fiscal Year ending December 31, 2022 (forecast)				0.00	0.00

(Note) Revisions to the dividend forecast announced most recently: No

3. Consolidated Financial Forecasts for the Fiscal Year Ending December 31, 2022 (January 1, 2022 to December 31, 2022)

	Revenue	Core operating profit	Operating profit	Profit before tax	Profit attributable to owners of parent
Fiscal Year ending December 31, 2022	Million yen / % 24,500 / 160.0	Million yen / % 6,600 / 61.2	Million yen / % 6,100 / 50.0	Million yen / % 6,000 / 57.7	Million yen / % 4,200 / 63.2

(Note) Revisions to the consolidated financial forecast announced most recently: Yes

From the consolidated financial forecasts for the fiscal year ending December 31, 2022 onward, the Company will disclose core operating profit, which excludes non-recurring revenues and expenses from operating profit, as a metric that indicates profitability on a recurring basis. Items that are excluded from operating profit to calculate core operating profit include accounting effects of business acquisitions and acquisition-related costs, impairment loss on property, plant and equipment, intangible assets and goodwill, gains or losses on compensation, settlements, non-recurring and significant gains and losses, and amortization of intangible assets from introduction of individual products or developments.

[Notes]

Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in change in scope of consolidation) : Yes

Newly included : 1 company (PDRadiopharma Inc.)

Excluded : –

(2) Changes in accounting policies and changes in accounting estimates

- | | |
|--|--------|
| 1) Changes in accounting policies required by IFRS | : None |
| 2) Changes in accounting policies due to other reasons | : None |
| 3) Changes in accounting estimates | : None |

(3) Number of shares issued (common stock)

- 1) Number of shares issued at the end of the period (including treasury stock)
- 2) Number of treasury stock at the end of the period
- 3) Average number of shares during the period

	As of September 30, 2022	130,010,400 shares	As of December 31, 2021	130,010,400 shares
1) Number of shares issued at the end of the period (including treasury stock)	As of September 30, 2022	179,405 shares	As of December 31, 2021	182,964 shares
2) Number of treasury stock at the end of the period	Nine months ended September 30, 2022	129,829,104 shares	Nine months ended September 30, 2021	128,593,281 shares

(Note) The number of treasury shares at the end of the period includes shares in the Company held by the Custody Bank of Japan, Ltd. (Trust Account E) (182,800 shares as of December 31, 2021 and 179,200 shares as of September 30, 2022). In addition, the shares in the Company held by the Custody Bank of Japan, Ltd. (Trust Account E) are included in treasury shares excluded from calculating the average number of shares during the period (188,056 shares for the nine months ended September 30, 2021 and 181,098 shares for the nine months ended September 30, 2022).

* Quarterly financial results reports are not required to be subjected to quarterly review by a certified public accountant or an audit firm

* Explanation on the appropriate use of operating forecasts and other special instructions

(Caution regarding forward-looking statements)

Financial forecasts and other statements regarding the future presented in these materials are based on information currently available and certain assumptions deemed to be reasonable and are not meant to be taken as commitment of the Company to achieve such results. Actual performance may differ substantially due to various factors.

(Adoption of International Financial Reporting Standards (IFRS))

IFRS is applied from the three months ended March 31, 2022, in place of the Japanese standard. Accordingly, the figures for the nine months ended September 30 of the previous fiscal year and the previous fiscal year are also calculated in accordance with IFRS for comparison purposes.